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ABSTRACT 
Phosphodiesterase 5A (PDE5A) specifically degrades the ubiquitous second messenger cGMP and 
experimental and clinical data highlight its important role in cardiac diseases. To address PDE5A 
role in cardiac physiology, three splice variants of the PDE5A were cloned for the first time from 
mouse cDNA library (mPde5a1, mPde5a2 and mPde5a3). The predicted amino acidic sequences of 
the three murine isoforms are different in the N-terminal regulatory domain. mPDE5A isoforms 
were transfected in HEK293T cells and they showed high affinity for cGMP and similar sensitivity 
to sildenafil inhibition. RT-PCR analysis showed that mPde5a1, mPde5a2 and mPde5a3 had 
differential tissue distribution. In the adult heart, mPde5a1 and mPde5a2 were expressed at 
different levels whereas mPde5a3 was undetectable. Overexpression of mPDE5As induced an 
increase of HL-1 number cells which progress into cell cycle. mPDE5A1 and mPDE5A3 
overexpression increased the number of polyploid and binucleated cells, mPDE5A3 widened HL-1 
areas and modulated hypertrophic markers more efficiently respect to the other mPDE5A isoforms. 
Moreover, mPDE5A isoforms had differential subcellular localization: mPDE5A1 was mainly 
localized in the cytoplasm, mPDE5A2 and mPDE5A3 were also nuclear localized. These results 
demonstrate for the first time the existence of three PDE5A isoforms in mouse and highlight their 
potential role in the induction of hypertrophy. This article is protected by copyright. All rights reserved 
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INTRODUCTION 
Phosphodiesterases (PDEs) are a large family of enzymes which hydrolyze the second messengers 
cAMP and/or cGMP playing a critical role in the regulation of cell response to different stimuli. 
Each member of PDE family consists of multiple variants produced by alternative splicing and/or 
usage of different transcription initiation sites (Conti and Beavo, 2007). PDE isoforms might show 
different hydrolytic kinetic and substrate affinity in specific tissues and a different cellular 
distribution (Lin et al., 2006). Among the other PDEs a great interest is given to PDE5A, a cGMP 
hydrolyzing enzyme, since its inhibition results useful for the treatment of erectile dysfunction 
(Goldstein et al., 1998) and, possibly, for cancer (Catalano et al., 2016; Zhu et al., 2005) and heart 
diseases (Lukowski et al., 2014). 
Regarding the expression in the tissues, in rodents Pde5a mRNA was found in platelets, lung, and 
cerebellum, brain, kidney, liver and heart (Kotera et al., 2000), in felines it was found in the heart 
(Shan and Margulies, 2011), and in dogs it was present at high levels in the lung (Lin et al., 2006). 
In human the highest levels of Pde5a mRNA were found in the cerebellum, kidney, pancreas, lung 
and heart (Kotera et al., 2000). PDE5A protein was detected at high levels in human platelets, lung, 
smooth muscle, including the vascular tissues of penis, brain and cerebellum, where it is 
particularly abundant in Purkinje neurons (Giordano et al., 2001; Shimizu-Albergine et al., 2003). 
In the heart, PDE5A regulates vascular tone, cardiomyocyte contraction, mitochondrial function and 
stress-response signaling (Isidori et al., 2015; Tsai and Kass, 2009). In adult cardiomyocytes 
PDE5A localizes at the z-disks of sarcomere and under the sarcolemma where it can degrade a 
cGMP pool generated by soluble guanylyl cyclase (sGC) (Takimoto et al., 2005). Upregulation of 
PDE5A expression was reported occurring in several cardiac pathological conditions (Pokreisz et 
al., 2009) and its inhibition leads to prevention and reversion of cardiac hypertrophy (Takimoto et 
al., 2005). 
Like for other PDEs, several isoforms exist for PDE5A. Three isoforms were identified in humans 
(PDE5A1, PDE5A2 and PDE5A3) (Kotera et al., 1998; Lin et al., 2000b). These proteins differ in 
the 5’ terminus of the respective mRNAs and consequently in the corresponding amino acid 
sequence at the N-terminus. The human PDE5A gene contains 21 exons spanning approximately 
100 kb and encodes three different mRNAs (Yanaka et al., 1998). These transcripts are yielded by 
the splicing of three alternative first exons in the pre-mRNA. PDE5A1 lengths for 875 amino acids, 
PDE5A2 for 833 amino acids and PDE5A3 for 823 amino acids. All three isoforms had similar 
cGMP-catalytic activities and similar inhibition sensitivity to sildenafil and zaprinast (Lin et al., 
2000a). Whereas PDE5A1 and PDE5A2 isoforms are expressed in all human tissues, PDE5A3 is 
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restricted to smooth muscle and cardiac muscle tissues. In mouse was identified so far only one 
isoform localized in chromosome 3 and corresponding to Pde5a1 (NM_153422.2) (Burns et al., 
1996). 
In order to address the physiological role of PDE5A in mouse cardiac muscle, the existence of 
additional isoforms was investigated. Three new isoforms were identified, cloned, biochemically 
characterized and their tissue expression evaluated. Flow cytometry and morphological analyses 
revealed specific biological activity of each isoform in cardiac cell line. 
 
 
MATHERIAL AND METHODS 
Ethics statement 
All procedures involving mice were approved by the Italian Ministry of Health and permission by 
the Animal Care and Committee of Sapienza University  was received. The procedures were 
performed according to the ethical guidelines for animal care of the European Community Council 
(directive 86/609/ECC). 
 
Mice 
CD1 mice of 60 dpp were obtained from Charles River Laboratories Italia (Calco, Lecco, Italy) and 
used in this study. At least 3 adult male and female (2-4 months of age) were used for organs 
collection in different experiments. For cardiomyocyte preparation were used 13-15 embryos (13.5 
dpc) or neonatal (1 dpp) mice. For adult cardiomyocyte preparations were used 3 mice. All mice 
were sacrificed by cervical dislocation. 
 
Plasmids 
Murine PDE5A isoforms were cloned into pCDNA3.1 and pEGFPC1 expression vectors 
respectively. PDE5A1 was cloned in the pCDNA3.1 expression vector between the EcoRV (5’) and 
XbaI (3’) restriction sites. PDE5A2 and PDE5A3 isoforms were cloned into pCDNA3.1 through 
replacement of the N-terminus of PDE5A1. The N-terminus of PDE5A2 (NCBI accession number 
KR816338.1) and PDE5A3 were amplified from whole murine embryonic RNA by RT-PCR using 
a reverse primer that annealed to a sequence including the KpnI site at 1600 bp of PDE5A 
sequence, and a forward primer that introduced a KpnI restriction site at the 5’ end of the product. 
Murine PDE5A isoforms were also cloned in pEGFP-c1 vector between the XhoI (5’) and SalI (3’) 
restriction sites. All generated plasmids were sequenced. 
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Cell cultures and transfection 
Primary cultures of mouse cardiomyocytes were prepared from 13.5 dpc hearts according to (Isidori 
et al., 2015) and from 1 dpp hearts as following: hearts were rapidly excised and placed into Hank’s 
solution, atria were cut off and ventricles were minced and digested by sequential incubation at 
37°C for 15 min with 100 μg/ml collagenase type II (Gibco-Life Technology, CA, USA) and 900 
μg/ml pancreatin (Sigma Aldrich, CA, USA) in ADS buffer (0.5M NaCl, 0.1M KCl, 0.1M glucose, 
0.1M hepes, 0.1M NaH2PO4, 0.1M MgSO4). Cells were resuspended in Dulbecco’s modified 
Eagle’s medium containing 10% v/v horse serum (Gibco-Life technology, CA, USA), 5% v/v fetal 
bovine serum (FBS) and 10 mg/ml gentamicin (Sigma Aldrich, CA, USA) and plated for 2 hours at 
37°C to remove the contaminating fibroblasts. The unattached cells were collected and plated onto 
collagen-coated tissue culture dishes in Dulbecco's modified Eagle's medium containing 10% v/v 
horse serum, 5% v/v FBS and 10 mg/ml gentamicin at a density of 3×10
5
 cardiac cells per 35-mm 
Petri dishes. 
HL-1 cells, kindly provided by Dr. Simona Nanni (Catholic University, Rome, Italy), were cultured 
in Claycomb medium (Sigma Aldrich, CA, USA) supplemented with 10 % v/v FBS (Sigma 
Aldrich, CA, USA), 0.2 mM norepinephrine, 2 mM L-glutamine, 1 U/ml penicillin and 1 μg/ml 
streptomycin solution (Sigma Aldrich, CA, USA) as previously described (Claycomb et al., 1998). 
NIH3T3 and HEK293T cell lines (ATCC, VA, USA) were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% v/v FBS, non-essential amino acids solution (Life 
Technologies, CA, USA) 2 mM L-glutamine, 1 U/ml penicillin and 1 μg/ml streptomycin solution 
(Sigma Aldrich, CA, USA). HL-1 transfection was performed using Lipofectamine 3000 (Life 
Technologies, CA, USA). Briefly 5 x 10
5
 HL-1/well were plated in 3.5 cm dishes and transfected 
after 24 h with PDE5A isoforms GFP-tagged vectors. Several DNA concentrations were tested and 
the lowest DNA concentration useful to achieve mPDE5A isoforms overexpression was used. 
Isoforms transfection efficiency ranged between 18-25% after 24h (Fig. S2C). 
 
Phosphodiesterase activity assay 
Cells were homogenized using a glass homogenizer (15 strokes, 4°C) in 20 mM Tris-HCl buffer pH 
7.2 containing 0.2 mM EGTA, 5 mM β-mercaptoethanol, 2% v/v antiprotease cocktail (Sigma 
Aldrich, CA, USA), 1 mM PMSF, 5 mM MgCl2, 0.1% v/v Triton X-100. The homogenates were 
centrifuged at 14000 g for 30 min at 4°C and pellets were re-suspended in the homogenization 
buffer and centrifuged at 14000 g for 30 min at 4°C. The first and second supernatants were then 
pooled and used for further analyses. PDE activity was measured at 30°C with the two-step method 
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described by Thompson and Appelman (Thompson and Appleman, 1971), using [H
3
]cGMP (Perkin 
Elmer, MA, USA). Aliquots of extracts were incubated in 60 mM HEPES pH 7.2 assay buffer 
containing 0.1 mM EGTA, 5 mM MgCl2, 0.5 mg/ml bovine serum albumin, 30 µg/ml soybean 
trypsin inhibitor, in a final volume of 0.3 ml. The reaction was started by adding tritiated substrate 
at indicated concentrations and stopped by adding 0.1 M HCl. For IC50 experiments, indicated 
sildenafil concentrations were added to the reaction mix. To evaluate the enzymatic specific activity 
(µmoles cGMP hydrolyzed/min./mg of enzyme), protein extracts from HEK293T, transfected with 
the indicated PDE5A isoforms, were assayed for PDE activity and 30 pmoles of cGMP hydrolytic 
activity for each sample were loaded onto a polyacrylamide gel, electrotransferred on PVDF 
membrane and probed with rabbit polyclonal PDE5A antibody. The amount of PDE5A in each 
immunoreactive band was evaluated by densitometric analysis and compared to different 
concentrations of purified mouse recombinant PDE5A (Abcam, UK). 
 
RT-PCR and RT-qPCR 
Total RNA was isolated from tissue samples or cell lines using TRIzol® reagent (Life 
Technologies, CA, USA) according to manufacturer's instruction. 1 µg of RNA was DNAse treated 
(Zymo Research, CA, USA) and reverse transcribed with random hexamer primers using a cDNA 
synthesis Kit (Promega, Mannheim, Germany). Primer sets used for semi-quantitative RT-PCR are: 
PDE5A1 Fw 5'-CACCATGGAACGAGCGGGCCCCAACTC-3', PDE5A2 Fw 5'-
ATGTTGCCCTTTGGAGACAAAACG-3', PDE5A3 Fw 5'-GTTTTGTTCTACAGAGACATG-3', 
PDE5A1-2-3 Rev 5'-CTTGAGCACTGGTCCCCTTCATC-3'; GAPDH Fw 5'-
ACTTTGGCATTGTGGAAGGG-3', Gapdh Rev 5'-CATGCCAGTGAGCTTCCCGTT-3'. 
Annealing was carried out at 58°C for all primer sets and up to 30 cycles were run for all 
amplifications except for Gapdh (23 cycles). Images were recorded with the Syngene G-box system 
(Syngene Bioimaging, Haryana, India) and intensities of the bands were quantitatively analysed 
using ImageJ Software (NIH, Bethesda, MD). Results represent the mean of at least three 
independent experiments and were normalized compared to the amount of housekeeping gene. 
For RT-qPCR, cDNA was prepared using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystem); the RT-qPCR was performed using either Syber Green (Promega) or TaqMan 
Gene Expression (Applied Biosystem) master mix by Applied Biosystems 7500 Real-Time PCR. 
Primers list for Syber Green RT-qPCR: 
Mef2c Fw 5'-CGATGCAGACGATTCAGTAG-3' and Mef2c Rev 5'-
ACTGTTATGGCTGGACACTG-3'; Nkx2.5 Fw 5'-CAATGCCTATGGCTACAACG-3' and 
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Nkx2.5 Rev 5'-GCCAAAGTTCACGAAGTTGC-3'; Mhy7 Fw 
5'AACTGGATGGTGACACGCAT-3' and Mhy7 Rev 5'-TGTGGTGGTTGAAGAACTGC-3'. 
Forward primers sequences for TaqMan RT-qPCR:  
PDE5A1: 5'-GACTGGGTGGAAGCGTG-3'  
(Probe: 5'-GGATGATCACCGGGACTTT-3');  
PDE5A2: 5'-AGAGTCTCCCGAGTCCAC-3'  
(Probe: 5'-CCCACCTTTGCTATGTTGCCCTTTG-3'); 
PDE5A3: 5'-CAGTATCCTTTTCCTTCCTTCAAG-3' 
(Probe: 5'-ACAGAGACATGGTCAACGCATGGT-3').  
Reverse primer sequence for TaqMan RT-qPCR: 5'-GGATGCCTTCCTTGCACA-3'. 
For quantification analysis, the comparative threshold cycle (Ct) method was used. The Ct values of 
each gene were normalized to the Ct value of Gapdh in the same RNA sample. The gene expression 
levels were evaluated by the fold change using the equation 2
-ddCt
.  
 
Western blot 
Tissues were lysated in 50 mM Tris HCl pH 8, 150 mM NaCl, 1% w/v NP-40, 0.5% w/v sodium 
deoxycholate, 0.1% w/v sodium dodecyl sulphate, 0.5 v/v mM dithiothreitol, 10 mM -
glycerophosphate, 0.1 mM sodium vanadate, and protease inhibitor cocktail (Sigma-Aldrich, CA, 
USA) or in 20 mM Tris-HCl buffer pH 7.2 containing 0.2 mM EGTA, 5 mM β-mercaptoethanol, 
2% v/v antiprotease cocktail (Sigma Aldrich, CA, USA), 1 mM PMSF, 5 mM MgCl2, 0.1% v/v 
Triton X-100 and were electrophoresed in polyacrylamide gels and transferred onto polyvinylidene 
fluoride (PVDF) (Amersham, Piscataway, NY) membranes. Primary antibodies were incubated 
overnight at 4°C, and secondary antibodies were incubated 1 hour at room temperature. Blots were 
probed with rabbit polyclonal PDE5A (Santa Cruz, CA, USA) and mouse monoclonal β-TUBULIN 
(Sigma-Aldrich, CA, USA) antibodies. In the competition experiments 0.2 µg/ml PDE5A antibody 
was previously incubated with 40 µg/ml of recombinant PDE5A for 1 hour at room temperature. 
Signals were detected with horseradish peroxidase (HRP)-conjugated secondary antibodies and 
enhanced chemiluminescence (Santa Cruz Biotechnology, CA, USA). Chemiluminescent images of 
immunodetected bands were recorded with the Syngene G-box system (Syngene Bioimaging, 
Haryana, India) and immunoblot intensities were quantitatively analysed using ImageJ Software 
(NIH, Bethesda, MD). Results represent the mean of at least three independent experiments and 
were normalized to the amount of housekeeping proteins. 
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Immunofluorescence Analysis 
Cells were fixed with ice cold 4% w/v paraformaldehyde in PBS and incubated for 10 minutes at 
4˚C, washed 2 times with PBS to remove any paraformaldehyde residue and permeabilized with 
0.1% v/v Triton®X-100 for 10 minutes at room temperature. Slides were then washed with PBS 
and incubated for 1 hour in 3% w/v BSA at room temperature. Primary antibodies (rabbit 
polyclonal PDE5A antibody, Abcam, UK, mouse monoclonal MHC antibody [MF20] from 
Hybridoma Bank and mouse monoclonal GFP antibody, SantaCruz Inc., CA, USA) were diluted in 
1% w/v BSA and left overnight at 4˚C. After three washings for 10 minutes in PBS, coverslips were 
incubated with the appropriate secondary antibody fluorescently labeled (fluorescein isothiocyanate, 
FITC or Texas red; Pierce, IL, USA) for 1 hour at room temperature. Nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI) (Life Technologies, CA, USA) and slides were finally mounted 
on microscope slides using MOWIOL® 4-88 reagent and left to dry for 1 hour then stored at 4˚C in 
the dark. Tissues were collected and fixed with 10% v/v Formalin for at least 24 hours at room 
temperature. Samples were dehydrated in an ascending series of alcohol concentrations (from 50% 
v/v to 100% v/v ethanol concentration) followed by toluene for a minimum of 4h. Tissues were 
placed in a bath of toluene paraffin for 2h in preparation for paraffin-embedding. The wax block 
was mounted on a microtome and sections of 5µm thickness were sliced. Slides were immersed in 
toluene for 20 minutes. Subsequently, the slides were rehydrated and then immersed in 2% v/v 
hydrogen peroxide/methanol solution for 20 minutes to block any endogenous peroxidase. Samples 
were examined by a Zeiss Axioskop2 plus microscope. Images were obtained with a Zeiss 
AxioCam HRc using the Axiovision software. 
Confocal images were instead acquired using a 63X Zeiss oil immersion objective on a Zeiss Pascal 
LSM510 laser-scanning confocal microscope (Carl Zeiss). An argon laser was used to excite 488 
nm fluorescently labeled secondary antibodies. Helium/neon lasers were used to excite 568 nm 
fluorescently labeled secondary antibodies. Zeiss Pascal software was used to gather image files. 
 
Analysis of HL-1 size 
Cell size quantification was performed 48 hours after transfection with PDE5A isoforms GFP-
tagged vectors labeling actin microfilaments with Phalloidin–Tetramethylrhodamine B 
isothiocyanate (TRITC) (Sigma-Aldrich, CA, USA). Nuclei were stained with DAPI. Cell area 
(µm
2
) or longitudinal and transversal axes length (µm) were measured using the software “Image J” 
(developed by USA National Institutes of Health). Images were acquired by Nikon Eclipse Ti-S 
microscope. 
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Subcellular fractionation 
Cells were trypsinized, harvested, lysed in IB-1 buffer (225 mM mannitol, 75 mM sucrose, 0.1 mM 
EGTA and 30-mM Tris–HCl pH 7.4) and homogenized by a Teflon pestle. Homogenate was then 
centrifugated at 600g for 5 min at 4 °C to precipitate nuclei. The supernatant was centrifugated 
again at 7,000 g for 10 min at 4 °C to recover the cytosolic fraction containing lysosomes and 
microsomes (supernatant). LAMIN A/C (goat polyclonal, Santa Cruz, CA, USA) was used as a 
marker of nuclear fraction and GAPDH (rabbit polyclonal, Santa Cruz, CA, USA) or β-TUBULIN 
(mouse monoclonal, Sigma-Aldrich, CA, USA) as cytoplasmic markers. 
 
Cell cycle 
HL-1 and NIH3T3 cells were initially plated at a density of 5 x 10
5
 cells/well in 3.5 cm dishes. Next 
day cells were transfected with PDE5A isoforms GFP-tagged vectors. Twenty four hours later, cells 
were synchronized with 0.5 mM L-Mimosine (Sigma-Aldrich, CA, USA). After 16 hrs, cells were 
washed with PBS and incubated in fresh culture media. At various times after release from the L-
Mimosine block the cells were treated with trypsin, harvested, and centrifuged at 2000 g for 5 min. 
The pellets were washed with PBS and then centrifuged again. Cells were fixed with 1% w/v 
paraformaldehyde for 1hr at 4°C, then centrifuged for 5 min at 300 g; supernatant was removed by 
aspiration and pellets washed with PBS. For cell membrane solubilization, 1 ml 70% v/v ethanol 
was added to the cell pellet, and cell suspension incubated overnight at 4°C. Fixed cells were 
washed with PBS, centrifuged and incubated for 3 hr at room temperature with propidium 
iodide/RNAse A solution (PI, 50 μg/mL, Sigma-Aldrich, CA, USA), ribonuclease (1 mg/ml Sigma-
Aldrich, CA, USA). The cell cycle distribution and DNA content were measured using a CyAn 
cytofluorimeter (Dako). 5 x 10
3
 cells were counted for each sample. The percentage of cells in 
different phases of the cell cycle was analyzed by FlowJo (TreeStar, Ashland, OR, USA). 
 
Statistical analysis 
Data obtained are presented as the means ± SD and  ± SEM from at least three separate experiments, 
each performed in triplicate. The significance of the data was analyzed using the Student's t-test for 
parametric data and the Mann–Whitney test with Bonferroni corrections for nonparametric data. 
P < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). 
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RESULTS 
Identification of mPDE5A isoforms 
The protein sequences of PDE5A in different mammalian species were retrieved from GenBank and 
aligned to compare their expression pattern. This analysis showed that up to three PDE5A isoforms 
were identified in the different species (Fig. S1A). All known PDE5As are encoded by a single 
gene and the different isoforms can be translated from alternative start sites, therefore each isoform 
usually possesses an unique N-terminal region. In mouse only one isoform was identified so far 
(Burns et al., 1996). To investigate the hypothesis that other PDE5A isoforms could be expressed in 
mouse tissues the NCBI Mus Musculus and Homo Sapiens genome sequences of the Pde5a locus 
were compared. The comparison between the mouse Pde5a first intron and the human gene 
revealed the presence of regions with a high homology degree [hPDE5 (NC_018915.2) 120524928-
120524828: m/PDE5 (NT_039240.7) 71815847-71815946; hPDE5 (NC_018915.2) 120516972-
120516481/ mPDE5 (NT_039240.7) 71822133-71822269]. This homology suggested that mPde5a 
gene may produce multiple protein isoforms. The first region of homology (Exon 1a) showed a 
newly identified potential start codon and the downstream sequence may encode 9 amino acids 
corresponding to the first exon of hPDE5A2. Similarly to the human gene, an in-frame ATG is 
within the second exon of the mPde5a gene which may represent an alternative translation start site 
for a third isoform. Since the comparative analysis of the sequences in the databank suggested that 
the murine gene can encode three PDE5A isoforms as the human gene, putative isoforms were 
named according to their equivalent human isoforms as mPDE5A1, mPDE5A2 and mPDE5A3. 
Fig. 1A shows the differences in N-terminal nucleotide sequence among the putative isoforms. 
 
mPDE5A isoforms show similar biochemical features 
To investigate the expression of mPde5A isoforms, total RNA from murine cardiomyocytes was 
extracted and retro-transcribed. mPde5a1 and mPde5a2 transcripts of expected size were detected 
as well as a band compatible for mPde5a3 isoform at minor intensity (Fig. S1B). These results 
strongly suggest that three mPde5a isoforms are expressed in mice like in humans. 
To evaluate the biochemical properties of the new putative identified mPDE5A isoforms, single 
isoform ORFs were obtained from a cDNA embryo library, cloned into pCDNA3.1 expression 
vector and then transfected into HEK293T cell line. Western blot analysis performed on cellular 
lysates of transfected cells showed cross-reaction between anti-PDE5A antibody and the cloned 
mPDE5A isoforms (Fig. S1C). Three bands of 99 ± 2.8 kDa, 91 ± 2.7 kDa and 89 ± 2.4 kDa were 
identified corresponding to mPDE5A1, mPDE5A2 and mPDE5A3, respectively. In the same 
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cellular lysates cGMP hydrolytic activity was assayed. In untransfected HEK293T cells a negligible 
level of endogenous cGMP-PDE activity was measured. Exogenous mPDE5A1 possess a Km 
higher than exogenous mPDE5A2 and mPDE5A3 (2.5 M ± 0.5 for mPDE5A1, 0.75M ± 0.01 for 
mPDE5A2 and 1.06 M ± 0.07 for mPDE5A3) indicating that mPDE5A1 is the isoform with the 
lowest affinity for cGMP (Fig. 1B). Since PDE5A is specifically inhibited by sildenafil at 
nanomolar concentrations (Ballard et al., 1998), an inhibition study was performed and 
demonstrated that all mPDE5A isoforms were inhibited by sildenafil with the same potency (IC50 
7.8 nM ± 1.11 for mPDE5A1, 5.2 nM ± 1.03 for mPDE5A2 and 4.7 nM ± 1.06 for mPDE5A3) 
(Fig. 1C). 
 
In vivo expression of mPDE5A isoforms 
To delineate the tissue distribution pattern of mPDE5A isoforms, a set of adult mouse organs was 
collected and PDE5A expression was analyzed both at mRNA and protein level. 
RT-PCR analysis revealed the presence of amplified cDNA bands of the expected molecular sizes 
in all examined organs except for the liver. (Figs. 1D); in the heart, mPde5a1 and mPde5a2 mRNAs 
were expressed whereas mPde5a3 mRNA was undetectable. 
The expression of PDE5A isoforms in murine tissues was also examined by Western blot analysis 
and quantified by densitometry (Fig. 1E). Since no specific antibodies for different PDE5A 
isoforms are currently available, a PDE5A pan antibody was used. PDE5A antibody identified 
protein bands which migrate as the recombinant mPDE5A isoforms (Fig. S1C). A band with the 
highest apparent molecular weight corresponding to PDE5A1 (MW 99 ± 2.8 kDa) was expressed in 
brain, cerebellum, heart, lung and ovary; a band with an apparent molecular weight corresponding 
to PDE5A2 (MW 91 ± 2.7 kDa) was expressed in brain, cerebellum, heart, lung, and ovary; a band 
with an apparent molecular weight corresponding to PDE5A3 isoform (MW 89 ± 2.4 kDa) was 
expressed in kidney and testis. The same pattern of protein expression was obtained in the absence 
of protease inhibitors suggesting that the different bands detected by western blot are not due to 
proteolytic digestion (data not shown). Furthermore, to test the specificity of the detected bands a 
competition experiment was performed using a protein homogenate of lung and heart tissues (Fig. 
S1D). Western blot analysis showed that the two bands of the apparent MW of 99 kDa and 91 kDa 
corresponding to PDE5A1 and PDE5A2 disappeared when the PDE5A antibody was incubated with 
purified recombinant PDE5A protein (Fig. S1D). Interestingly, the competition experiment revealed 
a further specific band at 104kDa in cerebellum, lung and ovary tissues (Fig. S1D). 
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Taken together these data show that mouse tissues express at least three PDE5A isoforms and 
mPDE5A1 and mPDE5A2 are both expressed in mouse heart. 
 
mPDE5A isoforms are differently expressed in heart and cardiomyocytes at different ages 
Expression of mPde5a isoforms was further investigated by mRNA and protein analyses in isolated 
cardiomyocytes and hearts obtained from 13.5 days post coitum (dpc), neonatal and adult mice 
(Figs. 2A-B). As displayed in Fig. 2A, mPde5a1 and mPde5a2 mRNA expression levels were 
found similar in samples obtained from hearts of different ages; mPde5a3 mRNA expression 
decreased with time becoming undetectable in adult heart. The mRNAs of the three isoforms were 
identified in samples obtained from cultured cardiomyocytes, indicating that mPde5as are 
specifically expressed in cardiomyocytes beside cells of different lineage. In particular, mPde5a1 
mRNA levels were lower in adult cardiomyocytes compared to cardiomyocytes isolated from 
embryos and neonatal mice. mPde5a2 mRNA expression levels were the highest and not modified 
during cardiac development. mPde5a3 mRNA expression levels gradually decreased and it was 
almost undetectable at the birth (Fig. 2B). Both mPde5a1 and mPde5a2  expression levels were  
recorded by real time PCR analyses in adult heart tissue and isolated cardiomyocytes (Fig. S1E). 
Due to the lack of specific antibodies for different PDE5A isoforms, neonatal and adult isolated 
cardiomyocytes were examined for total PDE5A localization by immunofluorescence analyses. 
Intracellular PDE5A expression pattern resulted in protein dispersion within the cytoplasm and in a 
localization at the z-lines (Figs. 2C-D). Interestingly, PDE5A nuclear localization was found both 
in neonatal and adult cardiomyocytes  (Figs. 2C-D) which was confirmed through nucleus-cytosol 
fractionation experiments performed on cellular homogenates obtained from neonatal 
cardiomyocytes (Fig. 2E). To investigate if PDE5A nuclear localization occurs also in vivo, 
immunofluorescence analyses were performed on neonatal and adult heart sections, confirming 
nuclear and cytoplasmic localization of PDE5A at tissue level (Figs. S2A-B). 
 
mPDE5A isoforms are differently localized in HL-1 cells 
 Endogenous PDE5A distribution pattern was first investigated in cardiac HL-1 cell line (Claycomb 
et al., 1998; White et al., 2004) and confocal analysis revealed that PDE5A was localized both in 
the nucleus and cytoplasm (Fig. 3A). It has been shown for other PDEs that alternative N-terminal 
domains drives different cellular distribution (Houslay and Adams, 2003; Sonnenburg et al., 1995). 
To verify if the N-terminus differences of mPDE5A isoforms lead to different subcellular 
localization, GFP-tagged isoforms were transfected in the HL-1 cells (Fig. 3 and S2C). The 
overexpression of GFP-tagged mPDE5A isoforms revealed a prevalent cytoplasmic localization of 
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mPDE5A1 (Fig. 3B), whereas mPDE5A2 and mPDE5A3 showed both nuclear and cytoplasmic 
localization. Taking advantage of GFP co-expression it was possible to quantify that 13.5% of 
mPDE5A1 overexpressing cells showed a PDE5A nuclear localization, whereas cells 
overexpressing mPDE5A2 and mPDE5A3 display a more frequent PDE5A nuclear localization 
(37.3% and 30.1%, respectively). Subcellular fractionation experiments confirmed that PDE5A is 
present both in the nucleus and cytoplasm of HL-1 cells (Fig. 3C). 
Taken together these data suggest that PDE5A localizes also within the nucleus and this event 
occurs more frequently for  mPDE5A2 and mPDE5A3 isoform. 
 
mPDE5A isoforms overexpression accelerates cell cycle and increases polyploidy of HL-1 cells 
No data are available on the specific role of PDE5A isoforms in the different tissues and how their 
expression can selectively modulate cell growth and differentiation. Indeed PDE5A suppression 
inhibits cell growth of cancer cells (Zhu et al., 2005). The effects of mPDE5A isoform 
overexpression was investigated in HL-1 cell cycle (Fig. 4A). GFP and mPDE5As-GFP 
overexpressing cells were synchronized and arrested in G1 phase by L-Mimosine treatment. After 
the removal of L-Mimosine, the percentage of cells in S phase increased in all samples. The 
percentage of HL-1 cells in S phase was slightly higher in mPDE5A isoforms overexpressing cells 
compared to control cells, even if it was not statistically significant. The percentage of cells in G2 
was higher 24 hours after L-Mimosine removal for all mPDE5A isoforms, suggesting an 
acceleration of the cell cycle (Fig. 4A). 
In G2 phase, cells contain the double of DNA content than in G1 phase. To assess the polyploidy 
degree of mPDE5A overexpressing cardiomyocytes, flow cytometry analysis of HL-1 cells 
overexpressing mPDE5A isoforms was performed. A significant increase of the percentage of 
polyploid cells (> 4N) was found in HL-1 cells overexpressing mPDE5A1 and mPDE5A3 (6.2% ± 
1.1 and 8.3% ± 0.9, respectively) compared to control cells (4.3% ± 0.7) whereas mPDE5A2 
overexpression did not trigger any significant change in the percentage of polyploid cells (3.2% ± 
0.5) (Fig. 4B). 
No differences in the specific activities were recorded between GFP-tagged and untagged isoforms 
indicating that the effects on cell cycle and polyploidy were due the intrinsic properties of the 
different PDE5A isoforms (Fig. S2D). 
These results indicate that mPDE5As overexpression triggers cell cycle progression and mPDE5A1 
and mPDE5A3 overexpression increases cardiomyocyte polyploidy. 
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mPDE5A isoforms overexpression induces cardiac hypertrophy 
The increase of the nuclear DNA content per cell could be due to the entrance of the cells in mitosis 
but in the case of cardiomyocytes it could be due to the presence of two nuclei per cell, which are 
associated to hypertrophy of cardiomyocytes (Ahuja et al., 2007; Liu et al., 2010). Several studies 
performed in humans and mice suggest an important role of PDE5A expression in the establishment 
of cardiac hypertrophy in pathological conditions (Pokreisz et al., 2009; Zhang et al., 2010), event 
that is accompanied by an increase of the polyploidy of cardiomyocytes (Ahuja et al., 2007; Liu et al., 
2010). 
To investigate if the increase of polyploid cells correlates with an increase of nuclei number per 
cell, the percentage of binucleated cardiomyocytes was evaluated by immunofluorescence staining 
of HL-1 cells overexpressing mPDE5A isoforms. In HL-1 control cells the binucleated cells were 
estimated to be 14.3% ± 3.5 of total GFP positive cells; mPDE5A1 overexpression almost doubled 
the percentage of binucleated cells (30.4% ± 5.1); mPDE5A2 overexpression increased the 
percentage of binucleated cell to a minor extent (22.6% ± 3.2) whereas mPDE5A3 overexpression 
was the most efficient to increase the number of binucleated cells (33.5% ± 5.2) (Fig. 4C). 
The increase of cell size is considered a marker of cardiomyocyte hypertrophy (Sadoshima and 
Izumo, 1997; Ahuja et al., 2007). For this reason cell area of HL-1 overexpressing mPDE5A 
isoforms was measured. Interestingly, only overexpression of mPDE5A3 but not mPDE5A1 and 
mPDE5A2 significantly increased HL-1 cells area (Fig. 4D). This result was confirmed through the 
measurement of longitudinal and transversal axes length of HL-1 cells overexpressing mPDE5A 
isoforms (Figs. S2E-F). In particular, mPDE5A3 significantly increased the length of transversal 
axis suggesting that this isoform could promote cell hypertrophy through specific rearrangement of 
cell shape (Fig. S2F). Furthermore RT-qPCR analysis revealed that hypertrophic markers were 
induced by PDE5A isoform overexpression (Fig. 4E). Notably, PDE5A3 was able to up-regulate all 
markers tested, confirming its potential role on HL-1 hypertrophy instauration (Fig. 4E). 
Overall these results suggest that mPDE5A1 and mPDE5A3 are the isoforms that prevalently 
increase DNA content and nuclei number per cell whereas, in addition, mPDE5A3 overexpression 
is able to enhance cell area by increasing cellular width. 
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DISCUSSION 
Multiple isoforms of PDE5A were described in different species, e.g. three isoforms in humans, two 
isoforms in rats and dogs (Lin et al., 2000b; Lin et al., 2003) and only one in mouse (Burns et al., 
1996). The presence of additional PDE5A isoforms in mouse was not further investigated even if 
Giordano and co-workers suggested the presence of different PDE5A isoforms in murine 
neuroblastoma N18TG2 cell line and in some murine tissues (Giordano et al., 2001). 
This study reports for the first time the identification and functional characterization of three  
different PDE5A isoforms in M. Musculus. mPDE5A1 showed the highest Km value, whereas all 
mPDE5A isoforms were similarly inhibited by sildenafil. We further examined the distribution of 
the new identified isoforms across tissues, their subcellular distribution, as well as functional and 
expressional regulation in physiological conditions. As a final outcome, the biological role of each 
isoform was investigated. RT-PCR analysis revealed a noticeably distinct distribution pattern for all 
mPDE5A isoforms among various mouse tissues. mPde5a1 and mPde5a2 were expressed at high 
levels in the lung, which can be in line with the primary role of PDE5A in vaso-constricting the 
pulmonary vasculature and its involvement in pulmonary hypertension (Hemnes and Champion, 
2006). In adult heart, mPde5a1 and mPde5a2 mRNAs were expressed whereas mPde5a3 was 
barely present. To be note that in adult heart PDE5A levels are relatively low and barely detectable 
in physiological conditions and they became elevated during hypertrophy (Nagendran et al., 2007). 
Protein distribution of the three isoforms was also assessed and it was found similar to our previous 
observations (Giordano et al., 2001). In brain, cerebellum, heart, lung and ovary two bands were 
clearly visible, the most intense corresponding, on the base of MW (99 ± 2.8 kDa), to the 
mPDE5A1 cloned isoform; the other band, of lower intensity, had the same MW (91 ± 2.7 kDa) of 
mPDE5A2 cloned isoform. Moreover, some tissues displayed a band of higher MW (104 ± 2.7 
kDa) respect to mPDE5A1, this band is specific as evaluated by competition experiments and it 
could represent a post-translational modification of mPDE5A isoforms. In brain and heart the 
presence of mPDE5A1 was evident, whereas the expression of mPDE5A2 isoform was barely 
detectable even if mPde5a2 mRNA was detected. It is still to understand why the protein is not 
translated. A band of 89 ± 2.4 kDa MW, corresponding to mPDE5A3, was detected only in testis 
and in kidney. In these two organs and in liver, an immunoreactive band of 96 ± 2.7 kDa MW 
between mPDE5A1 and mPDE5A2 isoforms was also detected. Similarly to PDE5A1 and PDE5A2 
expression in human (Lin et al., 2000a), mPDE5A1 and mPDE5A2 were expressed in all tissues 
analyzed except for liver. mRNA of mPde5a3 was found in several tissues but without the 
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corresponding protein expression suggesting that mPDE5A3 could be not translated or, 
alternatively, rapidly degraded. 
To further characterize regulation, catalytic activity, drugs sensitivity and subcellular localization of 
each isoform, exogenously expressed mPDE5A isoforms were transfected into HEK293T cell line. 
We observed that all three PDE5A isoforms possess similar substrate affinity (mPDE5A1 possess a 
Km higher than exogenous mPDE5A2 and mPDE5A3, indicating that this is the isoform with the 
lowest affinity for cGMP) and sildenafil sensitivity. This is in agreement with previous reports in 
which PDE5A human isoforms were tested for their cGMP-catalytic activity and sildenafil 
sensitivity showing that human PDE5A1 possess a Km and IC50 higher than human PDE5A2 and 
PDE5A3 (Lin et al., 2000a). 
It is likely that in various tissues and cell types the distinct N-termini of the three isoforms might 
endow them with specific regulatory properties, as well as specific subcellular localization. To 
assess this possibility the localization of the endogenous PDE5A in HL-1 cells was examined. The 
main compartments in which PDE5A was detected by immunofluorescence were: subsarcolemmal 
region, nucleus and myofilaments. Sarcomeric localization of PDE5A was extensively investigated 
in literature (Nagayama et al., 2008; Pokreisz et al., 2009; Takimoto et al., 2005). On z-lines, 
PDE5A is likely to be responsible of the regulation of a cGMP pool which, by PKG activation and 
consequent phosphorylation of Troponin I, should desensitize myofilaments to Ca2+, thus 
antagonizing the β-adrenergic stimulated inotropic effect (Lee et al., 2010; Senzaki et al., 2001). In 
the sarcoplasmatic reticulum, PDE5A might interacts with proteins involved in Ca
2+
 storing, as 
already reported by Wilson et al. (2008), where, controlling cGMP levels, should coordinate Ca
2+
 
release (Wilson et al., 2008). In a recent work, however, Lee and co-workers  (2015) showed that 
PDE9 but not PDE5 co-localizes with sarcoplasmic reticulum ATPase-2a (Lee et al., 2015). We and 
others reported a subsarcolemmal localization of PDE5A in cardiomyocytes (Isidori et al., 2015; 
Takimoto et al., 2005); indeed, it has been hypothesized that the subsarcolemmal pool of cGMP was 
under the exclusive control of PDE2 (Castro et al., 2006; Polito et al., 2013). Our observations 
could overturn the previous knowledge about phosphodiesterases targeting to that compartment. An 
unexpected cellular compartment that show a strong positivity for PDE5A was the nucleus, both in 
neonatal and adult cardiomyocytes and in HL-1 cell line, either by immunofluorescence and 
fractionation analyses. A nuclear localization in cardiomyocytes for this enzyme has never been 
described before, even though nuclear staining was shown in some papers (Lee et al., 2015) and a 
nuclear translocation of PKG was already demonstrated (Chen and Roberts, 2014). The sarcomeric 
and nuclear subcellular localization of endogenous PDE5A was also validated on neonatal and adult 
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hearts. In neonatal mice, the nuclear compartmentalization of PDE5A resulted less evident than 
adult hearts in which the percentage of PDE5A positive nuclei is less than 20%.  
One limitation for this study is the lack of specific antibodies for the three isoforms. The main 
hurdle to obtain specific antibodies is due to the overlapping coding sequences of PDE5A isoforms. 
We will attempt to develop specific antibodies directed against the three PDE5A isoforms by 
different strategies to further investigate their specific compartmentalization. In the meanwhile, to 
identify mPDE5A isoforms localization, cardiac HL-1 cells were transfected with constructs 
containing mPDE5A isoforms fused to a GFP-tag, allowing to visualize the transfected isoforms in 
distinct compartments. This cellular system is low transfectable but is the only available cell line of 
cardiac origin. A different subcellular distribution among the three isoforms was revealed; in 
particular mPDE5A1 resulted to be mainly localized in the cytoplasm, whereas mPDE5A2 and 
mPDE5A3 showed also an evident nuclear localization. 
Increased expression of PDE5A was reported in pathological conditions such as cancer  progression 
(Sponziello et al., 2015; Tiwari and Chen, 2013), but no data are available of the effect of increased 
intracellular level of PDE5A on cell cycle and cell growth.  
To investigate mPDE5A isoforms specific role, the effects induced by exogenous overexpression of 
each variant were evaluated on cell cycle and cell growth. The overexpression of the three isoforms 
induced a sustained cell cycle progression in cardiomyocytes (HL-1) and fibroblasts (NIH3T3) 
transfected cells (Fig. 4A and Fig. S2G), an effect that was not affected by PDE5A pharmacological 
inhibition (data not shown). The persistence of the effect on the cell cycle of PDE5A 
overexpression in the presence of PDE5A specific inhibitors suggests that it could be due to an 
intrinsic structural property of the protein. Indeed in smooth muscle cells PDE5A localizes at the 
level of centrosomes allowing to hypothesize that it could play an important structural role in the 
assembly of the mitotic spindle and, therefore, in the regulation of cell cycle progression (Dolci et 
al., 2006).  
In HL-1, overexpression of mPDE5A isoforms induced an increase of cells in G2 phase respect to 
mock cells, event associated to increased proliferation or to a G2 arrest. Indeed, HL-1 transfected 
with mPDE5A isoforms had a double content of DNA and double nuclei. Cardiomyocytes 
binucleation is considered a marker of hypertrophy (Nagendran et al., 2007). Also in our 
experiments the binucleation was accompanied by an increase in cell area following mPDE5A3 
isoform overexpression. Indeed, mPDE5A3 overexpression widen HL-1 area and transversal axis 
length up to 20% respect to control cells and induced hypertrophic markers unrevealing a potential 
role of this isoform in cardiac hypertrophy. This is in line with mRNA expression analysis showing 
  
This article is protected by copyright. All rights reserved 
18 
 
that mPde5a3 is downregulated in mouse heart and cardiomyocytes during the life in physiological 
conditions. 
In vitro and in vivo data indicate PDE5A3 increases in pathological cardiac conditions (manuscript 
in preparation). The understanding of the regulation of mPDE5A isoforms, their expression and 
activity in relation to their cellular context constitute an important step toward the improvement of 
the diagnostic, prognostic, and predictive values of PDE5A in heart disease or more widely in 
PDE5A-related diseases. 
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FIGURE LEGENDS 
 
Figure 1. mPDE5A isoforms identification, expression and activity. 
A. Nucleotide and amino acid sequences of mPDE5A isoforms showing alternative methionine (in 
bold) and the predicted molecular weight. Unique N-terminal sequence are underlined.  
B. Lineweaver-Burk plot of phosphodiesterase activity (1/pmoles cGMP hydrol./min/ml) of 
mPDE5A single isoforms assayed using different cGMP substrate concentrations. The Michaelis 
constant (Km) for each mPDE5A isoform was calculated. Data represent the mean of three 
determinations ± SD.  
C. Inhibition curve of mPDE5A single isoforms with sildenafil assayed through the cGMP 
hydrolysis radioactive assay. The assay was performed using 1μM cGMP as substrate 
concentration. The IC50 for each mPDE5A isoform was calculated. Data represent the mean of three 
different determinations ± SD.  
D. Representative image of RT-PCR analysis performed on cDNA from several mouse tissues 
showing a different distribution of the three Pde5A murine isoforms. Samples were normalized 
assaying the expression of Gapdh.  
E. Representative image of western blot on different mouse tissues (left panel). A PDE5A specific 
antibody was used to detect the presence of different PDE5A isoforms. TUBULIN was used as 
loading control. Molecular weights (kDa) of the observed bands are shown on blot right side with 
murine PDE5A isoforms; predicted molecular weights are shown in bold. Three determinations 
were performed on tissues from different mice.  
Densitometric analysis of western blot (right panel). Samples were normalized assaying the 
expression of  TUBULIN. Data represent the mean of three determinations ± SD. 
 
Figure 2. mPDE5A isoforms expression in the heart. 
A. Semi-quantitative RT-PCR performed on cDNA from total heart at different ages showing the 
relative abundance of each murine Pde5A isoform. Samples were normalized assaying the 
expression of Gapdh. Data represent the mean of three determinations performed in separate 
preparations ± SD. All p values were calculated using the Mann-Whitney test with Bonferroni 
corrections. * P < 0.05 and **P < 0.01. 
B. Semi-quantitative RT-PCR performed on cDNA from isolated cardiomyocytes at different ages 
showing the relative abundance of each murine Pde5A isoform. Samples were normalized assaying 
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the expression of Gapdh. Data represent the mean of three determinations performed in separate 
preparations ± SD. 
C. Immunofluorescence analysis on isolated neonatal cardiomyocytes from at least three different 
preparations showing PDE5A localization (green) and sarcomeres (MF20; red). Nuclei were stained 
with DAPI (blue). Scale bar = 10 μm.  
D. Immunofluorescence analysis on isolated adult cardiomyocytes from at least three different 
preparations showing PDE5A localization (green) and sarcomeres (MF20; red). Nuclei were stained 
with DAPI (blue). Scale bar = 30 μm.  
E. Western blot analysis on nucleus/cytosol fractions of isolated neonatal cardiomyocytes stained 
with PDE5A antibody showing the subcellular localization of endogenous PDE5A. Antibodies 
against LAMIN and GAPDH were used to distinguish nuclear and cytosolic fractions respectively. 
20-30μg of each fraction were loaded. At least three determinations were performed. 
 
Figure 3: mPDE5A isoforms display different subcellular localization in HL-1 cells. 
A. Confocal analysis on HL-1 cell lines showing endogenous PDE5A subcellular localization 
(green) and MF20 positivity (red). Nuclei were stained with DAPI. Three determinations were 
performed. Scale bar = 25 μm. 
B. Analysis of HL-1 after 48 hours transfection with GFP-tagged PDE5A single isoforms revealing 
a predominant cytoplasmic localization of PDE5A1 and a nuclear and cytoplasmic localization of 
PDE5A2 and PDE5A3 isoforms. Nuclei were stained with DAPI. Three determinations were 
performed. Scale bar = 10 μm. 
C. Western blot analysis on nucleus/cytosol fractions of HL-1 cells stained with PDE5A antibody; 
antibodies against LAMIN and TUBULIN were used to distinguish nuclear and cytosolic fractions, 
respectively. 30μg of each fraction were loaded. Three determinations were performed. 
 
Figure. 4: mPDE5A isoform overexpression induces cell cycle progression and increases HL-1 
cells cell size. 
A. Flow Cytometry analysis of HL-1 cell cycle after 24 hours transfection with GFP-tagged PDE5A 
isoforms. DNA content was measured by cell cycle synchronization with L-Mimosine and PI 
staining. Cell cycle was evaluated at different time point (T0, T4, T8 and T24) corresponding to 
hours after L-Mimosine removal from cell cultures. Bar graphs represent the percentage of cells in 
G1 phase (left panel), S phase (middle panel) and G2 phase (right panel). Diagram represents the 
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mean of three independent experiments ± SD. All p values were calculated using the Mann–
Whitney test with Bonferroni corrections. * P < 0.05 and ** P < 0.01. 
B. Flow Cytometry analysis of cellular ploidy of HL-1 cells after 48 hours transfection with GFP-
tagged PDE5A isoforms (left panel). Diagram (right panel) represents the percentage of haploid 
(2N), diploid (4N), or polyploid (>4N) according to PI staining. Data represents the mean of three 
independent experiments ± SD. All p values were calculated using the Mann-Whitney test with 
Bonferroni corrections. *P < 0.05, **P < 0.01 and ***P < 0.001. 
C. Analysis of cellular ploidy of HL-1 cells after 48 hrs transfection with GFP-tagged PDE5A 
isoforms. Diagram represents the percentage of cells with 1-4 nuclei stained with DAPI. Ten fields 
(approximately 10 cells/field) from each sample were randomly selected and the number of 
nuclei/GFP positive cells was determined. Data represents the mean of three independent 
experiments ± SD. All p values were calculated using a the Mann–Whitney test with Bonferroni 
corrections. *P < 0.05, **P < 0.01 and ***P < 0.001. 
D. Analysis of HL-1 area. Ten fields (approximately 10 cells/field) from each sample were 
randomly selected and the areas (μm2) of GFP-positive cells were measured by ImageJ Software. 
Diagram represents the mean of three independent experiments ± SD. All p value were calculated 
using a the Mann–Whitney test with Bonferroni corrections. *P < 0.05.  
E. RT-qPCR analysis of HL-1 cells after 48 hrs transfection with GFP-tagged PDE5A isoforms. 
Myosin heavy chain 7 (myh7), myocytes-specific enhancer factor 2C (Mef2C) and NK2 homeobox 
2.5 (Nkx2.5) were used as hypertrophic markers. Data are reported as fold change versus mock HL-
1 cells. Gapdh was used as loading control. Data represents the mean of three independent 
experiments ± SD. All p values were calculated using a the Mann–Whitney test with Bonferroni 
corrections. *P < 0.05, **P < 0.01 and ***P < 0.001. 
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